Introduction Primary mitochondrial disease is caused by either mitochondrial or nuclear DNA mutations that impact the function of the mitochondrial respiratory chain. Individuals with mitochondrial disorders have comorbid conditions that may increase their risk for poor bone health. The objective of this retrospective electronic medical record (EMR) review was to examine risk factors for poor bone health in children and adults with primary mitochondrial disease. Methods Eighty individuals with confirmed clinical and genetic diagnoses of primary mitochondrial disease at the Children's Hospital of Philadelphia (CHOP) were included in this study. Risk factors and bone health outcomes were collected systematically, including: anthropometrics (low BMI), risk-conferring co-morbidities and medications, vitamin D status, nutrition, immobility, fracture history, and, where available, dual energy x-ray absorptiometry (DXA) bone mineral density (BMD) results.
Introduction
Primary mitochondrial disease is a complex set of conditions characterized by dysfunction of the energy-generating mitochondrial respiratory chain. These conditions can be caused by mutations in either the nuclear or mitochondrial DNA that encodes its constituents or directly impacts its function (Chinnery 1993) . Despite considerable variability in clinical presentations, individuals with mitochondrial disease may be at risk for poor bone health, particularly if they are chronically ill, malnourished, and/or immobile. Mitochondrial disease can also increase risk for endocrine conditions that are known to adversely affect bone, including diabetes mellitus, hypoparathyroidism, growth hormone deficiency, and hypogonadism (Harvey and Barnett 1992; Mirza and Canalis 2015) , as well Communicated by: Daniela Karall Electronic supplementary material The online version of this article (doi:10.1007/s10545-017-0046-2) contains supplementary material, which is available to authorized users. as other conditions that increase risk for osteopenia and osteoporosis such as renal tubular acidosis and chronic liver disease.
Currently, our understanding of bone health in mitochondrial diseases is limited, and derives primarily from case studies of children with mitochondrial diseases and compromised bone health. For example, in one such report, a five year old boy with Kearns Sayre Syndrome (KSS) developed rickets with multiple bone deformities and fractures, with bone health that deteriorated to such an extent that he lost the ability to walk (Tzoufi et al. 2013) . Despite the potential substantial burden of osteopenia and osteoporosis in this population, and the clinical availability of anti-osteoporotic therapies, systematic studies of bone health in mitochondrial disease are lacking (Cholley et al. 2001; De Block et al. 2004) .
To address this need, and to lay the foundation for future prospective studies, the objective of this retrospective electronic medical record (EMR) review was to examine clinical risk factors for poor bone health in a cohort of individuals with primary mitochondrial disease. In addition, we evaluated key bone health outcomes, including fragility fractures, as well as bone mineral density (BMD), where available, from clinically obtained dual energy x-ray absorptiometry (DXA) scans.
Methods

Study design
This was a cross-sectional, observational, retrospective EMR review. Individuals were identified from an ongoing observational cohort study of primary mitochondrial disease at the Children's Hospital of Philadelphia (CHOP). This study has been approved by the CHOP Institutional Review (#08-6177, principal investigator MJF), and written informed consent was obtained from patients and/or guardians, as appropriate. Studies were conducted in accordance with the principles of the Declaration of Helsinki.
Inclusion and exclusion criteria
We included all individuals in the parent observational study (n = 80/101) who had undergone a clinical evaluation and genetic testing to confirm the diagnosis of primary mitochondrial disease in the context of at least one visit to the CHOP Mitochondrial Disease Clinical Center ( Supplementary  Fig. 1 ). Inclusion criteria were: i) clinical features consistent with primary mitochondrial disease and ii) molecular genetic evidence of a pathogenic mutation in mtDNA or nDNA in a gene known to be associated with dysfunction of complexes I-V of the respiratory chain (Stacpoole et al. 2012) .
EMR abstraction
A systematic data abstraction tool was created in a web-based instrument (REDCap). The factors outlined sections that follow were coded as Bpresent^, Babsent^, or Bmissing sufficient data^, for all available information through June 30, 2016. To guide this process, we used the detailed exclusion criteria created for the Bone Mineral Density in Childhood Study (BMDCS), a longitudinal study of skeletal development in healthy children that has been used to generate reference values for bone health in children and adolescents (Kalkwarf et al. 2007 ).
Demographics
Age, sex, and self-identified race and ethnicity were noted from the participant's most recent visit to CHOP, along with the age at the first CHOP contact and first visit to the CHOP Mitochondrial Disease Clinical Center.
Anthropometrics
Weight, height, and body mass index (BMI) from the most recent CHOP visit were noted. In addition, if any of the patients' height, weight, and BMI values were ever under the 3rd percentile for age and sex according to Center for Disease Control (Kuczmarski et al. 2002) pediatric reference values and/or corresponding adult reference values for underweight, this was noted as well . BMD is affected by extremes of weight (Kalkwarf et al. 2007 ).
Mitochondrial disease diagnosis
Genetic diagnoses and clinical syndromes were adjudicated by CHOP Mitochondrial Disease Clinical Center genetic counselors (CM, EMM) (Stacpoole et al. 2012) .
Serum 25-OH vitamin D levels
Vitamin D deficiency can be associated with adverse bone outcomes (Sunyecz 2008) . Participants were identified who had levels below 20 ng/ml or 30 ng/ml (at either the most recent visit or over all visits), since these thresholds are often used to define deficiency and insufficiency, respectively (Holick et al. 2011; Weaver et al. 2016) .
Diseases and conditions that predispose to poor bone health
We noted the presence of any chronic conditions known to be associated with poor bone health with a particular focus on: liver disease (acute or chronic), renal disease (renal tubular acidosis, nephrocalcinosis, nephrolithiasis, acute or chronic insufficiency), cancer, diabetes mellitus (DM), thyroid disease, adrenal disease, hypogonadism, and parathyroid disease.
We noted nutritional risk factors including: lactose intolerance, chronic gastrostomy or jejunostomy tube feeds, and/or home total parenteral nutrition (TPN) requirement.
Medications that influence bone integrity
For high-risk medications (Mirza and Canalis 2015; Mazziotti et al. 2016; Drezner 2004; Lindsey and Mohan 2016; Grieff and Bushinsky 2011) , we determined whether the patient was: i) currently receiving the medication; ii) had ever received the medication; or iii) had never been noted to receive the medication. For glucocorticoid use, only prolonged (more than 2 weeks), supra-physiologic systemic glucocorticoids were included (i.e., inhaled or topical use steroids were excluded). In addition, recorded history and/or current consumption of nutritional supplements including vitamin D2 or D3 and/or calcium were noted.
Immobility
Ambulatory status, as well as past or current occupational and/ or physical therapy were noted.
Fracture history and dual energy x-ray absorptiometry (DXA) findings
The approximate date of the fracture (either retrieved from office visits and/or the date of the diagnostic x-ray), location of fracture, and whether or not it was a traumatic fracture was noted. A fracture was considered traumatic if it occurred because of a high-impact force. A fracture was considered nontraumatic, or a fragility fracture, if it resulted from a force that would not normally cause a fracture, such as a fall from standing height or less (O'Flynn 2012). Fractures with unknown etiologies were labeled as such. If DXA scans were available, the T-score for adults and Z-score for children from a reference population based on gender, age, and race was recorded (Lewiecki et al. 2016) . For children, height-adjusted Z-scores for BMD were also calculated to adjust for the known effects of size on BMD measurements (Zemel et al. 2011) . Lumbar spine measurements were evaluated since they provide reproducible measures for BMD in infants and young children, according to the ICSD (Gordon et al. 2014 ). In addition, the presence of clinical conditions that could confound DXA results (including scoliosis, kyphosis, and lordosis) as determined either by diagnostic code, physician note, problem list, and/or x-ray result were also noted.
Statistical analysis
Clinical characteristics were summarized using means and standard deviations or medians and inter-quartile intervals, as appropriate. The number of risk factors for decreased bone health was calculated for each participant. These included: current or past BMI < 3rd percentile, high-risk chronic medical conditions or medications, requirement for gastrostomy/ jejunostomy tube feedings, lactose intolerance, home TPN, and inability to ambulate independently. If risk factors Boverlapped^, e.g., a chronic health problem plus the medication used to treat that chronic health problem, such as growth hormone for growth hormone deficiency, it was only counted once. Detailed fracture information was recorded.
Results
Risk factors for poor bone health
Clinical characteristics are presented in Table 1 and genetic diagnoses are in Table 2 . A summary of the risk factors for poor bone health is presented in Table 3 with additional details in Supplementary Table 1 (25-OH vitamin D levels), Supplementary Table 2 (nutritional considerations and immobility), Supplementary Table 3 (risk factors in the subpopulation with the m.3243A > G mutation) and Supplementary  Table 4 (risk factors in the subpopulation with the POLG mutations). In addition, we stratified the cohort based on both age and gender and present a summary of the risk factors in Supplemental Table 5 . Out of the 80 patients included, 71% (n = 57) were pediatric. In the entire cohort, 73% (n = 58) had at least one risk factor, 63% (n = 50) had at least two risk factors, 41% (n = 33) had at least three risk factors, and 30% (n = 24) had four or more risk factors for poor bone health. The median number of risk factors per pediatric participant was 2 (IQI 1, 2.5, range 0-8) and per adult participant was also 2 (IQI 0, 2, range 0-6). Almost one-third of the pediatric patients (32%, n = 18) and almost half of the adult population (48%. n = 11) had a medical condition related to their mitochondrial disease diagnosis that was considered a risk factor for osteoporosis.
With respect to anthropometrics, 6% of the pediatric cohort (three out of 50 with available current data) had a current BMI less than the 3rd percentile noted and 38% (15 out of 40 pediatric patients with available past data) and 10% (two out of 21 adult patients) had at least one BMI measurement less than the 3rd percentile noted previously. Notably, 58% (33 out of 56 pediatric patients where feeding type was noted) and 13% (three out of 23 adults) had an enteral feeding tube in place. With respect to mitochondrial disease subtype, we performed a sensitivity analysis of the 11 patients with the m.3243A > G mutation and found these patients to have a median of one risk factor (IQI 0, 2 range 0-3), Supplementary Table 3 . We also analyzed patients with the POLG mutation and found these patients to have a median of four risk factors (IQI 4,4 range 3-5), Supplementary Table 4 .
Fractures Table 4 provides an overview of clinical information from patients who experienced at least one lifetime fracture (n = 11), six pediatric patients and five adultpatients.A total of16fractureswere reported. Seven patients sustained a single fracture, three patients had two fractures, and one patient had three fractures (this individual was also the only patient in the study to have been clinically diagnosed with osteoporosis). The prevalence of any noted lifetime fracture in this mixed-age cohort of individuals with mitochondrial disease was 14% (11 out of 80). Six out of 16 fractures were fragility fractures, six were traumatic, and in four, etiology could not be determined. The median age at first fracture was 6.4 years (IQI 5.0-15.4, range 0.3-56). The sites that were fractured most often were the femur, humerus/elbow, and the radius/ulna. On average, these patients had 2.6 risk factors for poor bone health (range 0-8).
DXA Table 5 provides summarizes results for the seven individuals (six children, one adult) who underwent at least one DXA scan for evaluation of areal BMD. Five patients underwent one scan, and two patients underwent two scans.
Discussion
In summary, we have demonstrated a high prevalence of risk factors for poor bone health in a cohort of patients with primary mitochondrial disease. As evidence of the impact of this risk, a subset of the cohort also had experienced a fragility fracture, a highly morbid complication of decreased bone health. Despite these findings, only one individual had been prescribed anti-resorptive therapy (one individual with osteopenia was treated with pamidronate).
Over half of this well-curated cohort had at least two clinical risk factors for low BMD. Although this study was not designed to examine the difference between children and adults, we noted that DM is more common in adults (22%) than children (1.8%), and also nutritional factors are noted more commonly in children than in adults (65% versus 17%). Overall, several of these risk factors occurred frequently and deserve additional consideration. For nearly one fifth of the cohort, renal tubular acidosis (RTA) and/or chronic renal insufficiency was present. Even relatively mild acidification defects are associated with decreased bone health (Weger et al. 1999) , thus RTA and/or other metabolic acidosis is a clear risk factor for low BMD. Vitamin D insufficiency (30%) or deficiency (17%) was present in a substantial portion of the cohort in whom levels had been measured (n = 30). Abnormal absorption of vitamin D may result from liver or other GI disease, and abnormal vitamin D metabolism can occur in chronic kidney disease. Vitamin D deficiency is also one of many potential mechanisms underlying decreased bone health related to use of some anti-epileptic medications (Shiek Ahmad et al. 2016) . Vitamin D supplementation was noted explicitly in 23% of the cohort. Since vitamin D deficiency is a modifiable risk factor for poor bone health, vitamin D repletion (63) 10% (8) 3.8% (3) 3.8% (3) 13% (10) 1.3% (1) 1 Race and ethnicity were ascertained separately strategies (Misra et al. 2008 ) may require more dedicated attention and individualized titration in this population. In addition, there may be benefits beyond bone to adequate vitamin D levels, including improved muscle oxidative phosphorylation capacity (Sinha et al. 2013) . Diabetes mellitus (DM) is another prominent risk factor for osteoporosis and one of the most common endocrine manifestations of primary mitochondrial disease (Schaefer et al. 2013; Whittaker et al. 2007 ), present in 8% (n = 6) of this cohort. Multiple mechanisms have been posited for the association between DM and osteoporosis. For example, the accumulation of advanced glycation endproducts can cause osteoblast apoptosis and decrease bone formation (Khan and Fraser 2015) . In affected patients, careful DM management, including surveillance for potential effects on bone, is warranted. Multiple medications increase the risk of osteoporosis (Panday et al. 2014) . Nearly half of this cohort (45%, n = 36) either had taken or were currently taking at least one potentially high-risk medication. Of these, systemic glucocorticoids and anticonvulsants were frequently utilized, 10% (n = 8) and 38% (n = 30), respectively. Each of these medications has been shown to have deleterious effects on bone turnover (Toth and Grossman 2013) . Importantly, abnormal bone turnover may adversely affect bone quality in a manner that is not reflected in BMD as assessed by DXA, but may nonetheless increase the risk of fracture.
Beyond clinical risk factors, there may also be a direct adverse effect of mitochondrial disease at the level of skeletal maturation and bone turnover. Osteoclasts are rich in mitochondria, and energy availability seems to affect their resorptive capacity (Miyazaki et al. 2003) . The activity of cytochrome c oxidase, complex IV of the mitochondrial Patients with at least one risk factor: 75% (n = 43) 65% (n = 15) 73% (n = 58)
Patients with at least two risk factors: 65% (n = 37) 56% (n = 13) 63% (n = 50)
Patients with at least three risk factors: 47% (n = 27) 26% (n = 6) 41% (n = 33) Patients with more than three risk factors: 37% (n = 21) 13% (n = 3) 30% (n = 24) (1) 18% (14) Liver disease (acute, chronic, elevated liver enzymes) 12% (7) 9% (2) 11% (9) Diabetes mellitus 1.8% (1) 22% (5) 7.5% (6) Thyroid disease 7% (4) 9% (2) 7.5% (6) Gonadal disorder 3.5% (2) 17% (4) 7.5% (6) Five out of 11 patients had taken or were currently taking anticonvulsant medication, 4 out of 11 had a G/J tube, 5 out of 11 had at least one 25-OHD level noted to be below the specified thresholds, 5 out of 11 patients utilized an assisted walking device, and 2 out of the 11 patients were noted to have been taking or currently taking vitamin D supplements. *exact date of fracture unknown, date of x-ray was used to calculate age; **none of these patients had undergone a DXA scan respiratory chain, has been shown to regulate the activity of osteoclasts necessary for adaptive bone remodeling (Miyazaki et al. 2003) . Some insights on the direct effects of mitochondria on bone can also be gleaned from studies in model systems. Mice expressing the defective mitochondrial DNA polymerase (PolgA) (Trifunovic et al. 2004 ) are models of the corresponding disease in humans. Homozygous knock-in mice with deficient versions of PolgA (the catalytic subunit of the mitochondrial DNA polymerase) develop kyphosis and osteoporosis. Of patients in our cohort, 6% (n = 5) had pathogenic mutations in POLG. Interestingly, all of these patients had three or more risk factors for poor bone health. Specifically, all five patients used enteric feeding tubes, four out of five were taking anticonvulsants, and two had renal disease ( Supplementary Table 4 ). This example illustrates that genetic and/or clinical sub-type may impact the risk for adverse bone health outcomes. There is a basis for this clinical observation in model systems. Specifically, in a mouse model of POLGrelated mitochondrial disease, osteoblasts were found to have respiratory chain dysfunction and animals had poor bone health (Dobson et al. 2016) . Another approach to understanding the role of mitochondria in bone health is to look for bioenergetic defects in apparently otherwise healthy individuals with pathological fractures. One study examined the mitochondrial genome from blood samples of 15 men with vertebral fractures and found a novel 3.7 kb mitochondrial DNA deletion, which included genes encoding complex I subunits in the mitochondrial respiratory chain, in two of these patients (Varanasi et al. 1999 ). It has also been suggested that osteoporosis due to aging could be in part attributable to the accumulation of mitochondrial DNA mutations (Papiha et al. 1998 ). In the present study, we are not able to isolate the direct effects of mitochondrial dysfunction on bone from the indirect effects of mitochondrial dysfunction on bone related to comorbidities and medications. However, from the growing body of literature on the role of mitochondria in skeletal health, we might expect mitochondrial dysfunction to exert an independent, adverse effect on bone; future studies can address this important issue.
Fractures were sustained by 14% of this cohort. In 55% (n = 6 out of 11), the first fracture was noted to occur before age 9 years. The age distribution and exposure profile of any cohort will substantially influence the expected fracture rate, as reflected by age-related fracture incidence values in reference populations (Weber et al. 2015) . Although to our knowledge there are no other large studies reporting fractures in individuals with mitochondrial diseases, fracture rates can be examined in other conditions for comparison. For example, patients with Friedreich's Ataxia (FRDA), also develop neurological disease, DM, and limited mobility. A study assessed 28 patients with FRDA and found that 21% (n = 6) had a history of bone fracture, and the same percentage had a BMD Z score of −2 or worse (Eigentler et al. 2014) . A retrospective study including 221 patients with spina bifida (ages 2-58) documented 42 fractures (Dosa et al. 2007) , yielding a similar rate as observed in our present study (42/221, 19% versus 16/80, 20%) . Similar to individuals with mitochondrial myopathies, boys with Duchenne muscular dystrophy (DMD) have decreased muscle strength that may predispose them to falls, as well as to poor bone health and fractures. One cross-sectional study in DMD (median age 12 years) reported a lifetime fracture rate of 21% (McDonald et al. 2002) . These studies suggest relatively comparable rates of poor bone health and fracture in other conditions.
The excess rate of epilepsy in mitochondrial disease also deserves consideration. Patients with epilepsy have multiple risk factors for osteoporosis and fractures including epilepsyinduced falls, anti-epileptic medications, immobility, low BMI and increased prevalence of endocrine comorbidities including GH deficiency and hypothyroidism (Wei and Lee 2015) . A recent study assessing risk factors for poor bone health in 260 patients with epilepsy (not necessarily related to mitochondrial disease) found that 11% had osteoporosis and 38% (99 of 258 patients) had at least one lifetime fracture (Fedorenko et al. 2015) . Of the 106 patients, 52% of those who had undergone DXA scans had low BMD.
A significant proportion of patients with primary mitochondrial disease were also noted to have a spinal curvature, which may also affect BMD and its clinical assessment. • A consensus statement from the Mitochondrial Medicine Society includes a recommendation that a combination of resistive and progressive exercise, with supervision, is indicated for patients with mitochondrial diseases. Exercise and/or physical therapy will improve muscle strength and coordination, which may prevent future falls and resulting fractures.
1. Defined by the ISCD as: 2 or more long bone fractures by age 10 years, or 3 or more long bone fractures by age 19 years Several studies have found that as spinal curvature increases, BMD decreases (Pavlovic et al. 2013; Sadat-Ali et al. 2008) .
The presence of spinal curvature should be taken into account when considering risk factors for poor bone health. Anti-resorptive and/or anabolic therapies can be considered for patients with severe osteopenia or osteoporosis. Bisphosphonates are a mainstay of osteoporosis therapy, but there is a limited evidence base in mitochondrial disease, in particular in children. One patient in the cohort was diagnosed with osteopenia, and was started on pamidronate therapy at the age of 13 years, one month after his first DXA scan. This patient received 0.4 mg/kg the first day, and 0.75 mg/kg the following day. Four months later, he received 1.1 mg/ kg. A second DXA scan was performed approximately one year after the third pamidronate infusion, which showed a 29% improvement in lumbar BMD and 8.3% improvement in left femoral neck BMD. The only noted adverse effect was fever after the first infusion. The safety, tolerability, and efficacy of anti-osteoporotic therapies across age and disease subtypes in mitochondrial disease are important areas for future study.
This study has strengths and limitations. We have confined our analysis to genetically defined mitochondrial disorders with rigorously curated clinical data, a clear strength. The study's design was retrospective and cross-sectional, an inherent limitation. We suspect that the true burden of adverse bone outcomes in this cohort may be even higher than the lower limits reported here. Despite this limitation, the present study provides initial estimates of the burden of disease, demonstrates the wide variation in practice with respect to bone health assessment, and provides evidence of opportunities to optimize bone health with supportive measures, including physical activity and nutrition. A summary of clinical considerations drawn from our study is presented in Table 6 (Bishop et al. 2014; Zemel et al. 2010; Alexandru and So 2012; Murphy et al. 2008; Parikh et al. 2015; Barry and Kohrt 2008; Kanis et al. 1994) . Future studies should evaluate specific strategies to promote bone health in this high-risk population.
Compliance with ethical standards
Conflict of interest None.
Details of funding
The funding for this observational study was provided by NIH K23DK102659, (SEM).
Ethical guidelines This study has been approved by the CHOP IRB, and was conducted in accordance with the principles of the Declaration of Helsinki of 1975 as revised in 2000. All written informed consent was obtained from patients and/or guardians, as appropriate.
